The CEO of Moderna warned European countries Tuesday that dragging out negotiations to purchase its promising new Covid-19 vaccine will slow down deliveries, as other nations that have signed deals will get priority.
For more coronavirus news, visit our dedicated page.
“It is clear that with a delay this is not going to limit the total amount but it is going to slow down delivery,” Stephane Bancel said in an interview with AFP.
Moderna announced this week that its experimental vaccine is almost 95 percent effective in protecting people from the coronavirus, further boosting hopes of an end to the pandemic after Pfizer released similar findings last week about its vaccine.
Bancel said the US, by contrast, has already reserved 100 million doses since early August and several million doses are now in storage awaiting US regulatory approval, probably in December.
- Coronavirus: What does COVID-19 vaccine effectiveness mean?
- Coronavirus: Breakthrough COVID-19 vaccine tech could help defeat other diseases
- Coronavirus: Israel’s Benjamin Netanyahu chases deals with top vaccine developers
- Putin, Netanyahu discuss producing Russia's coronavirus vaccine in Israel
- Coronavirus: Travel restrictions challenge COVID-19 vaccine rollout, airlines warn
- Coronavirus: CureVac deal takes EU’s COVID-19 vaccine supplies close to 2 billion
- Moderna coronavirus vaccine stability enables distribution in rural areas: Official
- Coronavirus vaccine will not be enough; to complement other tools we have: WHO chief
- Britain expects to roll out Pfizer coronavirus vaccine before Christmas: Minister
- Coronavirus: Scientist says vaccine could halve COVID-19 transmission
- Coronavirus: Moderna says COVID-19 vaccine 94.5 pct effective